
    
      The primary study objective is to assess the efficacy of G-ER dosed in either of the
      following regimens:

      G-ER 1200mg daily (single evening dose)

      G-ER 1800mg daily (dosed asymmetrically; 600mg AM/1200mg PM)

      compared to placebo in reducing the average daily frequency and severity score of moderate to
      severe hot flashes in postmenopausal women after 4 weeks and 12 weeks of treatment with a
      stable dose, compared with the baseline week.
    
  